New drug combo targets hidden leukemia cells in early trial
NCT ID NCT06284486
First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This study tests whether two drugs, venetoclax and revumenib, can control minimal residual disease (MRD) in acute myeloid leukemia (AML) patients. MRD means small numbers of cancer cells remain after initial treatment, raising the risk of relapse. The trial enrolls about 8 people aged 12 and older with specific genetic types of AML. The goal is to see if the combination is safe and can reduce or eliminate these leftover cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
-
Johns Hopkins University
RECRUITINGBaltimore, Maryland, 21218, United States
Contact Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.